Drug Database
Back to search

Belgium· BE-AMP-SAM209964-00

NeoRecormon 4000 IU

A erythropoietin product containing epoetin beta, registered in Belgium by Roche Registration. The same ATC class is registered in 12 of our 19 countries.

ATC B03XA01

Checked against FAMHP / AFMPS (Belgium) on

Informational only — not a medical device.

SOURCE REGISTER · BEFAMHP / AFMPS (Belgium)normalisedNeoRecormon 4000 IUATCB03XA01REGISTER NO.BE-AMP-SAM209964-00PACKS LISTED3CHECKEDSeptember 26, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about epoetin betaAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Erythropoietin is registered in 12 of 19 countries.

Countries holding a registration under ATC B03XA01 (erythropoietin), each read from that country’s own register.

  • This record: Belgium, from FAMHP / AFMPS (Belgium)
  • 8 of them publish a price we can compare per daily dose
Search erythropoietin products by name

Erythropoietin · ATC B03XA01

12 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

FAMHP / AFMPS (Belgium)
Active substance
Epoetin Beta
Manufacturer
Roche Registration
Country
Belgium (BE)
ATC code
B03XA01
ATC class
Erythropoietin
Defined daily dose
1 TSD, E
Reimbursed
Not published by this register
Source register
FAMHP / AFMPS (Belgium)
Last checked
September 26, 2026

Packs & prices · 3

  • be_apb
    0764969
  • be_apb
    1522408
  • be_apb
    7737398

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

18 interactions on record for erythropoietin.

Graded by severity as the source publishes them — 5 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check erythropoietin against other medicinesHow interaction checks work

Erythropoietin · interactions on record

18 records

  • 5 severe
  • 3 moderate
  • 10 minor

Most severe, free to view

  • CarfilzomibL01XG02severe
  • CarfilzomibL01XX45severe
  • ThalidomideL04AX02severe
  • LenalidomideL04AX04severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Erythropoietin in 17 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All erythropoietin products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Erypo
  • Czechia · Eprex
  • Germany · Erypo Fs
  • Spain · Eprex
  • France · Eprex
  • United Kingdom (Northern Ireland) · Eprex
  • Greece · Eprex
  • Iceland · Abseamed, Binocrit
  • Italy · Eprex
  • Liechtenstein · Binocrit, Epoetin Alfa Hexal
  • Luxembourg · Eprex
  • Netherlands · Eprex
  • Norway · Abseamed, Binocrit
  • Portugal · Eprex
  • Slovenia · Eprex

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/b470c65d-534f-49bd-8d3e-80a458a0b1e7
GET /v1/drugs/b470c65d-534f-49bd-8d3e-80a458a0b1e7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Solution for injection",
  "source": "afmps",
  "status": "AUTHORIZED",
  "name_en": "NeoRecormon 4000 IU",
  "name_fr": "NeoRecormon 4000 IU",
  "name_nl": "NeoRecormon 4000 IU",
  "amp_code": "SAM209964-00",
  "strengths": [
    "4000.0000"
  ],
  "pack_count": 3,
  "substances": [
    "Epoetin Beta"
  ],
  "medicine_type": "ALLOPATHIC",
  "atc_description": "Erythropoietin",
  "authorisation_numbers": [
    "EU/1/97/031/041",
    "EU/1/97/031/042"
  ]
}
API referenceMCP serverPlans

See everything about erythropoietin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console